Cue Biopharma, Inc., a clinical-stage therapeutics company, focuses on developing various therapies for immunological disorders. The company's lead asset is CUE-221, an anti-IgE antibody with a dual-mechanism of action currently in Phase 2 development for allergic diseases. It also developed the...
45 insider purchases on record · latest filing 2025-12-30.
Insiders have also filed 37 sale transactions at CUE.